Skip to main content
Premium Trial:

Request an Annual Quote

David Hoffmeister, Eric Winzer, Ludwig Huber, William Knight, Grant Thornton, Laura Francis, Kevin Farr, Charles Haggerty, Udo Klein, Steven Knapp, Kate Gilbert, Dick Rubin

Invitrogen on Tuesday named David Hoffmeister as chief financial officer, replacing Eric Winzer, who held the post since 2002. Winzer will remain on the Invitrogen staff and will manage the installation of enterprise resource planning for the company, typically a lengthy and expensive information technology project. Hoffmeister comes to Invitrogen after 20 years at McKinsey & Co., where he left as a senior partner specializing in mergers and acquisitions.

Ludwig Huber was named compliance fellow for the life sciences and chemical analysis division of Agilent Technologies. His duties will include helping the company identify and evaluate compliance-related initiatives for pharmaceutical laboratory customers. Huber has been at Agilent and parent Hewlett Packard since 1978.

Bruker BioSciences this week named William Knight as its chief financial officer, effective Oct. 25. Knight previously was CFO for Anika Therapeutics of Woburn, Mass. Previous to that, he served in that role for Zycos, a private biotechnology company, as well as for NMT Medical, and Zoll Medical. Knight is a certified public accountant and began his career as an auditor with Grant Thornton. He holds a bachelor’s degree in business administration from the University of Wisconsin. He replaces Laura Francis who in July announced her resignation, effective Sept. 1. She was CFO for Bruker AXS, and then the merged Bruker BioSciences.

Beckman Coulter this week announced that Kevin Farr, chief financial officer for Mattel, has been elected to its board of directors, effective Oct. 8. Farr holds an MBA from Northwestern University’s J L Kellogg Graduate School of Business. He received his bachelor’s degree from Michigan State University. The addition of Farr to Beckman Coulter’s board raises the number of company directors from 10 to 11. Farr will stand for election at the next annual stockholder meeting in April, the company said.

Another Beckman director, Charles Haggerty, retired chairman and CEO of Western Digital, was named to the board of directors of Imation, a computer storage manufacturer.

Udo Klein was named to the new position of senior vice president of drug development for Cellular Genomics of Branford, Conn. Klein was senior vice president of research and development at EntreMed. Previous to that, he was a manager in the pharmaceutical division of Bayer.

Steven Knapp has joined the Center for Applied Genetic Technologies at the University of Georgia as a Georgia Research Alliance Eminent Scholar in crop genomics. Knapp joins Georgia after 20 years at Oregon State University where he was chairman of the Crop and Soil Science Department. His new position in the UGA College of Agricultural and Environmental Sciences is partially funded by joint contributions from the GRA and the Georgia Seed Development Commission.

Kate Gilbert, formerly consumables product manager, has been promoted to director of marketing of Ciphergen Biosystems, replacing Dick Rubin, who left the company in August.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.